2023
DOI: 10.1016/j.prp.2023.154346
|View full text |Cite
|
Sign up to set email alerts
|

A review on the role of ADAMTS9-AS2 in different disorders

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 40 publications
0
7
0
Order By: Relevance
“…Due to this, WWC2-AS2 is believed to be crucial to cancer development. Appealingly, ADAMTS9-AS2 has been widely investigated [ 37 , 38 ]. Recent research showed that ADAMTS9-AS2 could restrict the deterioration of esophageal cancer and it also has the ability to function as a prognostic lncRNA in LUAD [ 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…Due to this, WWC2-AS2 is believed to be crucial to cancer development. Appealingly, ADAMTS9-AS2 has been widely investigated [ 37 , 38 ]. Recent research showed that ADAMTS9-AS2 could restrict the deterioration of esophageal cancer and it also has the ability to function as a prognostic lncRNA in LUAD [ 39 ].…”
Section: Discussionmentioning
confidence: 99%
“…This study demonstrated the upregulation of ADAMTS9‐AS2 expression in hPDLCs under mechanical compression, which facilitated cell migration by interacting with ADAMTS9 under mechanical compression. ADAMTS9‐AS2 is located in exon 6 of chromosome 3p14.1 37 . Previous studies involving ADAMTS9‐AS2 have mainly focused on the pathogenesis of different types of cancers, including salivary adenoid cystic carcinoma, ovarian cancer, esophageal cancer, and non‐small cell lung carcinoma 38–41 .…”
Section: Discussionmentioning
confidence: 99%
“…ADAMTS9-AS2 is located in exon 6 of chromosome 3p14.1. 37 Previous studies involving ADAMTS9-AS2 have mainly focused on the pathogenesis of different types of cancers, including salivary adenoid cystic carcinoma, ovarian cancer, esophageal cancer, and non-small cell lung carcinoma. [38][39][40][41] ADAMTS9-AS2 affects ADAMTS9 expression and influences cell migration in liver and bladder cancers.…”
Section: Anastasi Et Al and Militi Et Al Reached The Opposite Conclusionmentioning
confidence: 99%
“…ADAMTS9-AS2 has both tumour suppressor and proto-oncogenic functions depending on the type of cancer and can be used as a biomarker for cancer. Abnormal expression levels of this lncRNA measured in plasma or tissue have diagnostic value, with changes reported in patients with malignancy of lung, oesophageal and prostate cancer [243], and lung adenocarcinoma [112,244,245]. The decreased expression of ADAMTS9-AS2 in tumour tissue correlates with poor prognosis and shorter survival in patients with oesophageal cancer [246], lung adenocarcinoma [242], breast cancer, and bladder urothelial carcinoma [243].…”
Section: Emerging Lncrna Biomarkers Of Gbmmentioning
confidence: 99%
“…This lncRNA is also abnormally upregulated in other malignancies, with significantly increased levels in ovarian cancer tissue [217], while in lung adenocarcinoma, its level is reduced [242]. ADAMTS9-AS2 is involved in several major signalling pathways, including PI3K/AKT and MEK/Erk, and interacts with many miRNAs (in most cases as a sponge) [243]. ADAMTS9-AS2 has both tumour suppressor and proto-oncogenic functions depending on the type of cancer and can be used as a biomarker for cancer.…”
Section: Emerging Lncrna Biomarkers Of Gbmmentioning
confidence: 99%